Indonesia’s PT BioFarma ready to produce IndoVac Covid-19 vaccine

 Indonesia’s PT BioFarma ready to produce IndoVac Covid-19 vaccine


PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in the manufacturing of IndoVac, a Covid-19 vaccine brand it has developed since November 2021.

Honesti Baasyir, president director of PT BioFarma, said the company collaborated with the USA’s Baylor College of Medicine, a private, independent health sciences center in Houston, Texas, to develop IndoVac, a recombinant protein subunit vaccine produced from yeast.

PT Bio Farma has completed Phase I and Phase II clinical trials and is currently in the Phase III stage to produce the primary series vaccines or two vaccine doses for everyone aged 18 years and older.

IndoVac uses vaccine technology platforms which are compatible with the equipment and facilities within our factories. The technology platforms for protein recombinant vaccines also offer other benefits: they can be adapted to the new strains of Covid-19. Results from Phase I and Phase II clinical trials showed that IndoVac offers quality safety and efficacy, not less competitive than other Covid-19 vaccines, the company noted.

Applying for EUA permit
Mr Baasyir said BioFarma has had intense communication with the Indonesian Food and Drug Administration (BPOM) since July 2022 to provide the necessary data, so that BPOM can release the Emergency Use Authorization (EUA) permit for IndoVac's primary series vaccines in the near term.

The EUA, released by a country's regulatory agency, is a permit for medical supplies (including vaccines) and medications during a public health emergency. In Indonesia, the BPOM plays the key role as a regulatory gatekeeper of medicines and vaccines used in the country.

After securing all the necessary permits, Bio Farma is ready to move on to the next stage, which is producing IndoVac's primary series vaccines massively. At the first stage, BioFarma plans to produce a maximum of 20 million doses of primary series vaccines, before this can be further increased to 40 million doses in 2023, as the company expands its production facilities.

Image: coronavirus_credit_deposit_photos

Comments

Popular posts from this blog

Effects Of Meditation

How to Train your Brain to keep you healthy and

Polio declared a disaster emergency in New York after more poliovirus found